A Study to Assess the Pharmacodynamic Effect of Single Doses of AZD9977 in Healthy Male Subjects

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-09-30

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase I, Randomized, Single-Blind, Crossover Study to Assess the Pharmacodynamics of AZD9977 following Single-Dose administration to healthy male subjects

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Japanese Healthy Participants With Single and Multiple Ascending Dose Administration

NCT03801967

Heart Failure

COMPLETED PHASE1

To Assess the Safety, Tolerability and Pharmacokinetics of AZD2820 After Single Ascending Doses

NCT01332214

Healthy

COMPLETED PHASE1

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects

NCT02632526

Healthy Male Subjects Cardiovascular Disease

COMPLETED PHASE1

Study to Investigate the Activity of AZD5122 When Given as a Single Dose to Healthy Male Subjects

NCT00984477

Healthy

COMPLETED PHASE1

Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses ofAZD2551

NCT00860353

Healthy

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will be a phase I study to assess the pharmacodynamics of AZD9977 following single-dose administration to healthy male subjects. It is a single-blind (with regards to AZD9977 and AZD9977 Placebo), randomized, four-treatment, four-period crossover design, with a potential 5th and 6th randomized cross-over treatment period. In this study eplerenone is used as a positive control and fludrocortisone will be used as a challenge agent. In addition the safety, tolerability and pharmacokinetics will be assessed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pharmacodynamics Healthy Subjects

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Sequence 1

Period 1: fludrocortisone + eplerenone + AZD9977 Period 2: fludrocortisone + eplerenone + AZD9977 Placebo Period 3: fludrocortisone + AZD9977 Placebo Period 4: fludrocortisone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment

Group Type EXPERIMENTAL

AZD9977 oral suspension

Intervention Type DRUG

AZD9977 oral suspension, single dose

AZD9977 placebo oral suspension

Intervention Type DRUG

oral suspension, single dose

Fludrocortisone, tablets

Intervention Type DRUG

Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)

Eplerenone, tablets

Intervention Type DRUG

100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)

Treatment Sequence 2

Period 1: fludrocortisone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + eplerenone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment

Group Type EXPERIMENTAL

AZD9977 oral suspension

Intervention Type DRUG

AZD9977 oral suspension, single dose

AZD9977 placebo oral suspension

Intervention Type DRUG

oral suspension, single dose

Fludrocortisone, tablets

Intervention Type DRUG

Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)

Eplerenone, tablets

Intervention Type DRUG

100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)

Treatment Sequence 3

Period 1: fludrocortisone + AZD9977 Period 2: fludrocortisone + AZD9977 Placebo Period 3: fludrocortisone + eplerenone + AZD9977 Placebo Period 4: fludrocortisone + eplerenone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment

Group Type EXPERIMENTAL

AZD9977 oral suspension

Intervention Type DRUG

AZD9977 oral suspension, single dose

AZD9977 placebo oral suspension

Intervention Type DRUG

oral suspension, single dose

Fludrocortisone, tablets

Intervention Type DRUG

Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)

Eplerenone, tablets

Intervention Type DRUG

100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)

Treatment Sequence 4

Period 1: fludrocortisone + eplerenone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment

Group Type EXPERIMENTAL

AZD9977 oral suspension

Intervention Type DRUG

AZD9977 oral suspension, single dose

AZD9977 placebo oral suspension

Intervention Type DRUG

oral suspension, single dose

Fludrocortisone, tablets

Intervention Type DRUG

Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)

Eplerenone, tablets

Intervention Type DRUG

100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)

Treatment Sequence 5

Period 1: fludrocortisone + eplerenone + AZD9977 Period 2: fludrocortisone + eplerenone + AZD9977 Placebo Period 3: fludrocortisone + AZD9977 Placebo Period 4: fludrocortisone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment

Group Type EXPERIMENTAL

AZD9977 oral suspension

Intervention Type DRUG

AZD9977 oral suspension, single dose

AZD9977 placebo oral suspension

Intervention Type DRUG

oral suspension, single dose

Fludrocortisone, tablets

Intervention Type DRUG

Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)

Eplerenone, tablets

Intervention Type DRUG

100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)

Treatment Sequence 6

Period 1: fludrocortisone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + eplerenone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment

Group Type EXPERIMENTAL

AZD9977 oral suspension

Intervention Type DRUG

AZD9977 oral suspension, single dose

AZD9977 placebo oral suspension

Intervention Type DRUG

oral suspension, single dose

Fludrocortisone, tablets

Intervention Type DRUG

Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)

Eplerenone, tablets

Intervention Type DRUG

100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)

Treatment Sequence 7

Period 1: fludrocortisone + AZD9977 Period 2: fludrocortisone + AZD9977 Placebo Period 3: fludrocortisone + eplerenone + AZD9977 Placebo Period 4: fludrocortisone + eplerenone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment

Group Type EXPERIMENTAL

AZD9977 oral suspension

Intervention Type DRUG

AZD9977 oral suspension, single dose

AZD9977 placebo oral suspension

Intervention Type DRUG

oral suspension, single dose

Fludrocortisone, tablets

Intervention Type DRUG

Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)

Eplerenone, tablets

Intervention Type DRUG

100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)

Treatment Sequence 8

Period 1: fludrocortisone + eplerenone + AZD9977 Placebo Period 2: fludrocortisone + AZD9977 Period 3: fludrocortisone + eplerenone + AZD9977 Period 4: fludrocortisone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment

Group Type EXPERIMENTAL

AZD9977 oral suspension

Intervention Type DRUG

AZD9977 oral suspension, single dose

AZD9977 placebo oral suspension

Intervention Type DRUG

oral suspension, single dose

Fludrocortisone, tablets

Intervention Type DRUG

Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)

Eplerenone, tablets

Intervention Type DRUG

100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AZD9977 oral suspension

AZD9977 oral suspension, single dose

Intervention Type DRUG

AZD9977 placebo oral suspension

oral suspension, single dose

Intervention Type DRUG

Fludrocortisone, tablets

Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)

Intervention Type DRUG

Eplerenone, tablets

100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Provision of signed and dated written informed consent prior to any study specific procedures.
2. Healthy male subjects aged 18 to 50 years with suitable veins for cannulation or repeated venipuncture.
3. Male subjects must accept to comply with the restrictions for sexual activity provided to them.
4. Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.
5. Optional: Provision of signed and dated written informed consent for genetic research.

Note: Participation in exploratory biomarker research is mandatory. If a subject declines to participate in the genetic component of the study, there will be no penalty or loss of benefit to the subject. The subject will not be excluded from other aspects of the study described in this protocol.
6. Able to understand, read and speak the English language.

Exclusion Criteria

1. History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the potential subject at risk because of participation in the study, or influences the results or the potential subject's ability to participate in the study.
2. History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
3. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of first dosing with investigational medicinal product (IMP).
4. Any clinically significant abnormalities in hematology, clinical chemistry or urinalysis results, as judged by the investigator.
5. Abnormal findings in vital signs, after 10 minutes resting in the supine position, defined as any of the following:

* Systolic blood pressure (SBP) \< 90 mmHg or ≥ 140 mmHg
* Diastolic blood pressure (DBP) \< 50 mmHg or ≥ 90 mmHg
* Pulse \< 45 or \> 85 beats per minute (bpm)
6. Any clinically significant abnormalities on the 12-lead electrocardiogram (ECG), as judged by the investigator.
7. Any positive result at screening for serum hepatitis B surface antigen (HBsAg), hepatitis C antibody, and human immunodeficiency virus (HIV) antibodies.
8. Known or suspected history of drug abuse, as judged by the investigator.
9. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of first dosing. The period of exclusion begins 3 months after the final dose or one month after the last visit whichever is the longest.

Note: Subjects consented and screened, but not randomized in this study or a previous phase I study, are not excluded.
10. Plasma donation within one month of screening or any blood donation/blood loss \> 500 mL during the 3 months prior to screening.
11. History of severe allergy/hypersensitivity or ongoing clinically significant allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD9977.
12. Current smokers or those who have smoked or used nicotine products within the previous 3 months.
13. Positive screen for drugs of abuse, alcohol or cotinine at screening or for each admission to the study center.
14. Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to first dosing.
15. Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during 2 weeks prior to first dosing, or longer if the medication has a long half-life.
16. Known or suspected history of alcohol or drug abuse or excessive intake of alcohol, as judged by the investigator.
17. Involvement of any AstraZeneca or study site employee or their close relatives.
18. Subjects who previously received AZD9977.
19. Judgment by the investigator that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements.
20. Known allergy to eplerenone or fludrocortisone or any of the constituents (including lactose, which is a constituent of Florinef™).
21. History of galactose intolerance.
22. Any infections or at risk of infection (surgery, trauma, or significant infection) within 90 days of screening, or history of skin abscesses within 90 days of screening.
23. Presence, history or family history of long QT syndrome, hypokalemia, hyperkalemia or Torsades de Pointes.
24. Serum potassium \< 3.5 mmol/L or ≥ 5.0 mmol/L at screening or for each admission to the study center.
25. Presence or history of active peptic ulcer.
26. History of any psychiatric disorder (including affective, psychotic, behavioral, irritability, anxiety, sleep disturbances and cognitive disorders) which required specialist psychiatric review.
27. Excessive intake of caffeine containing drinks or food (e.g., coffee, tea and chocolate) as judged by the investigator.
28. Subjects who are vegans or have medical dietary restrictions (vegetarians may be included in the study).
29. Subjects who cannot communicate reliably with the investigator.
30. Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
31. In addition, any of the following is regarded as a criterion for exclusion from the genetic research:

* Previous bone marrow transplant.
* Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes